Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345696
Status:
COMPLETED
Last Update Posted:
2011-08-24
First Post:
2006-06-27
Brief Title:
1stline Study Capecitabine Administered on Continuous Way Plus OxaliplatinBevacizumab Every 2weeks in Metastatic CCR
Sponsor:
Unidad Integral de Investigación en Oncología SL
Organization:
Unidad Integral de Investigación en Oncología SL
Study Overview
Official Title:
Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determinate progression free survival after 9 months of treatment
Detailed Description:
To look for a new chemotherapy management to get less acute and chronic toxicity andor an easier administration treatment line
This study tries to demonstrate an alternative chemotherapy schemecontinuous polychemotherapy regimen with less dose with the added effect of the monoclonal antibody Bevacizumab
This study tries to demonstrate an alternative chemotherapy schemecontinuous polychemotherapy regimen with less dose with the added effect of the monoclonal antibody Bevacizumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None